Montalvan 2021.
| Methods | Trial design: single‐centre, randomised, non‐blinded control trial pilot study Type of publication: abstract only Setting: hospitalised participants Recruitment dates: 81 randomised (40 low‐dose, 41 high‐dose dexamethasone) Country: Honduras Language: English Number of centres: single‐centre Trial registration number: not reported Date first posted: October 2021 |
| Participants | Age: (mean ± SD) of 56.9 ± 14.9 and 57.5 ± 16.5 for low and high‐dose dexamethasone respectively Gender: low‐dose n = 17 (42.5%) male and n = 23 (57.5%) female vs the high‐dose n = 29(70.7%) male and n = 12(29.3%) female Proportion of confirmed infections: not reported Ethnicity: not reported Number of participants (recruited/allocated/evaluated): not reported/81/81 (40 low‐dose, 41 high‐dose dexamethasone) Severity of condition according to study definition: not reported Severity of condition according to WHO score: not reported Co‐morbidities: not reported Inclusion criteria: not reported Exclusion criteria: not reported Previous treatments (e.g. experimental drug therapies, oxygen therapy, ventilation): not reported |
| Interventions | Treatment details of intervention group (e.g. dose, route of administration, number of doses)
Treatment details of control group (e.g. dose, route of administration, number of doses): dexamethasone 6 mg /day Concomitant therapy (e.g. description of standard care): not reported Duration of follow‐up: not reported Treatment cross‐overs: not reported Compliance with assigned treatment: not reported |
| Outcomes | Primary study outcome: reduction in mortality and intubation Additional study outcomes: hospital‐acquired infections, risk of becoming critically ill and requiring intubation |
| Notes | Date of publication: October 2021 Sponsor/funding: not reported |